Life Style

Obesity drugs achieve an average weight loss of 24 kg in clinical trials

Weekly injections of drugs that mimic natural appetite-suppressing hormones lost an average of 22.5 percent of body weight


May 4, 2022

A model of the hormone GLP-1 designed to mimic tyrzepatide

Molecule / Scientific Photo Library / Alamy

Obese people lost an average of 24 kilograms when treated with the highest doses of new starvation blockers in large clinical trials.

“It’s really exciting. The weight loss they show is dramatic-it’s as much as you get with a successful weight loss surgery,” he says. Michael Cowley He was not involved in the research at Monash University in Melbourne, Australia.

The drug, called tilzepatide, is a combination of synthetic mimetics of two hormones known as GLP-1 and GIP, which the intestines spontaneously release after eating to give a feeling of fullness.

In late-stage clinical trials, more than 2,500 people in nine countries weighing an average of 105 kilograms at baseline were asked to inject tyrzepatide weekly at low, medium, and high doses, or placebo for 72 weeks. rice field. What they were taking.

The highest dose of tyrzepatide is most effective, Weight loss of 24 kilograms on average, Equivalent to a 22.5 percent loss of body weight. In comparison, participants taking placebo lost only 2 kilograms on average.result Announced on April 28th According to Lily, a major US pharmaceutical company that develops medicines.

June 2021, US Food and Drug Administration Approved another obesity drug called semaglutide It contains a GLP-1 imitation by itself, without adding a GIP. Semaglutide also promotes weight loss, Average 15 percentSuggests that the GIP component added to tilzepatide gives an additional boost, Cowley says.

Like semaglutide, tyrzepatide can cause side effects such as nausea, vomiting, diarrhea, and constipation, and seems to be exacerbated at high doses.

However, doctors’ experience with semaglutide has shown that these side effects can be avoided by starting low doses and gradually increasing patients. The same is true for tilzepatide. Joseph Proyet At the University of Melbourne, Australia.

One of the benefits of obesity medicines is that they can be discontinued if needed, says Proietto. “The downside of weight loss surgery is that you can never eat a regular diet, even on special occasions,” he says. “You can also do this with medicine.”

Again, the downside of tyrzepatide and semaglutide is that they need to be given continuously, but “when surgery is done, it’s done,” says Cowley.

“Actually, it’s a discussion between individuals and doctors about which option is right for them, but now it’s great to have another option,” he says.

Prior to applying for approval for the drug, Lily said she would monitor participants who started clinical trials with prediabetes for another 104 weeks to see if tyrzepatide could also help prevent type 2 diabetes.

Sign up for free Medical examination Newsletter that provides reliable health, diet and fitness news every Saturday

Details of these topics:

Obesity drugs achieve an average weight loss of 24 kg in clinical trials

Source link Obesity drugs achieve an average weight loss of 24 kg in clinical trials

Back to top button